Literature DB >> 17922405

Seminal plasma reduces the effectiveness of topical polyanionic microbicides.

Sarju Patel1, Ehsan Hazrati, Natalia Cheshenko, Benjamin Galen, Heyi Yang, Esmeralda Guzman, Rong Wang, Betsy C Herold, Marla J Keller.   

Abstract

The objective of this study was to test the activity of microbicides against herpes simplex virus type 2 (HSV-2) introduced in seminal plasma. We found that seminal plasma interfered with the activity of PRO 2000 and of cellulose sulfate, increasing by 100-fold the concentration of drug required to inhibit 90% of viral plaque formation. Seminal plasma competitively inhibited binding of the microbicides to the HSV-2 envelope. Most of the interference was found in a high molecular-weight fraction; tandem mass spectrometry identified the proteins as fibronectin-1 and lactoferrin. In a murine model, the interference translated in vivo into a loss in protection. We found that 2% PRO 2000 gel protected 100% of mice challenged intravaginally with HSV-2 introduced in PBS, whereas only 55% of mice were protected if virus was introduced in seminal plasma (P=.0007, log rank test). If these findings are reflective of what occurs in humans, modifications to microbicides to ensure that they retain activity in the presence of seminal plasma are indicated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922405     DOI: 10.1086/522606

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  57 in total

1.  Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides.

Authors:  Onofrio Zirafi; Kyeong-Ae Kim; Nadia R Roan; Silvia F Kluge; Janis A Müller; Shibo Jiang; Benjamin Mayer; Warner C Greene; Frank Kirchhoff; Jan Münch
Journal:  Sci Transl Med       Date:  2014-11-12       Impact factor: 17.956

2.  Dynasore disrupts trafficking of herpes simplex virus proteins.

Authors:  Mascha B Mues; Natalia Cheshenko; Duncan W Wilson; Leslie Gunther-Cummins; Betsy C Herold
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

Review 3.  Development of topical microbicides to prevent the sexual transmission of HIV.

Authors:  Robert W Buckheit; Karen M Watson; Kathleen M Morrow; Anthony S Ham
Journal:  Antiviral Res       Date:  2009-10-27       Impact factor: 5.970

Review 4.  Clinical parameters essential to methodology and interpretation of mucosal responses.

Authors:  Brenna L Anderson; Susan Cu-Uvin
Journal:  Am J Reprod Immunol       Date:  2011-01-12       Impact factor: 3.886

5.  Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.

Authors:  Ana M Chamoun-Emanuelli; Michael Bobardt; Bernard Moncla; Marie K Mankowski; Roger G Ptak; Philippe Gallay; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

Review 6.  Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities.

Authors:  Charlene S Dezzutti; Florian Hladik
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

7.  Griffithsin protects mice from genital herpes by preventing cell-to-cell spread.

Authors:  Briana Nixon; Martha Stefanidou; Pedro M M Mesquita; Esra Fakioglu; Theodore Segarra; Lisa Rohan; William Halford; Kenneth E Palmer; Betsy C Herold
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

Review 8.  Rectal microbicide development.

Authors:  Ian McGowan; Charlene Dezzutti
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

9.  In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide.

Authors:  Lisa C Rohan; Bernard J Moncla; Ratiya Pamela Kunjara Na Ayudhya; Marilyn Cost; Yunda Huang; Fang Gai; Nicole Billitto; J D Lynam; Kara Pryke; Phillip Graebing; Nicole Hopkins; James F Rooney; David Friend; Charlene S Dezzutti
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

10.  Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials.

Authors:  Marla J Keller; Pedro M M Mesquita; N Merna Torres; Sylvia Cho; Gail Shust; Rebecca P Madan; Hillel W Cohen; Julie Petrie; Tara Ford; Lydia Soto-Torres; Albert T Profy; Betsy C Herold
Journal:  PLoS One       Date:  2010-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.